During the past decade, Kailin Xu conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Kailin Xu" are "Acute Myeloid Leukemia Refractory" (1 trials), "Acute Myeloid Leukemia, in Relapse" (1 trials) and "Multiple Myeloma" (1 trials). Many other conditions were trialed in "Kailin Xu" in a lesser frequency.

Most popular intervention types in "Kailin Xu" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "anti-BCMA/GPRC5D CAR-T CELL" (1 trials) and "anti-siglec-6 CAR-T cell therapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kailin Xu" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Kailin Xu". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Kailin Xu, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kailin Xu, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".